-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Ventyx Biosciences to Neutral, Announces $14 Price Target

Benzinga·01/08/2026 13:30:03
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar downgrades Ventyx Biosciences (NASDAQ:VTYX) from Buy to Neutral and announces $14 price target.